一个先进的水凝包装系统,具有渐进的输送和层到层的响应,用于糖尿病伤口愈合
Ying Liu1, Tianqi Liu2, Zhenye Zhu3
1State Key Laboratory of Advanced Welding and Joining, Research Centre of Printed Flexible Electronics, School of Materials Science and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, PR China; Department of Chemistry, College of Sciences, Northeastern University, Shenyang 110819, PR China; Changzhou Zhitai Shengchuang Technology Co., Ltd., Changzhou 213000, PR China.
Acta biomaterialia
|November 1, 2024
概括
这项研究引入了一种新型的对葡萄糖有反应的水凝,用于糖尿病患者的伤口愈合. 智能系统通过控制炎症和促进组织修复来加速愈合,提供了一个有前途的新疗法.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 药物输送系统 药物输送系统
背景情况:
- 糖尿病伤口表现出延迟的炎症和受损的修复,阻碍有效的愈合.
- 现有的治疗方法往往难以控制药物释放并解决复杂的炎症环境.
研究的目的:
- 开发一种渐进的,逐层响应的水凝,用于动态的糖尿病伤口管理.
- 创建一个智能药物输送系统,适应炎症和修复阶段的独特需求.
- 提高抗炎药物的可溶性和稳定性,以提高治疗疗效.
主要方法:
- 制造一种对葡萄糖有反应的水凝,使用酸 Ester 键 (4-arm-poly(乙烯基醇) succinimidyl glutarate 和 3-aminophenylboronic 酸).
- 加入一种活性药物成分的离子液体 (API-IL),包括二二烯和L-卡尼丁,具有抗炎作用.
- 集成对矩阵金属蛋白酶-9 (MMP-9) 敏感的凝微囊,用于控制药物释放.
- 评估水凝的风湿性质,以模仿人类皮肤.
主要成果:
- 开发的水凝表现出葡萄糖的反应性,使得可控的物理化学性质的调整.
- 该API-IL配方成功解决了二二和L-卡尼丁的溶解性和稳定性问题.
- 敏感的MMP-9微囊确保了精确,均的药物分发,防止过早释放.
- 水凝的风湿学特征与人体皮肤的特征非常相似,这表明它具有良好的生物相容性.
结论:
- 开发的逐层响应的水凝系统为糖尿病伤口愈合提供了安全,高效和智能的方法.
- 这种先进的药物输送系统有效地控制炎症,并加速糖尿病伤口的修复过程.
- 这些发现是显著的进步,在治疗复杂伤口方面具有很大的临床应用潜力.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:18Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233
01:31Diabetic Foot Ulcer
33
Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory...
33